From what I saw, "not good". But at least the results weren't "bad."
The abstract's use of the word 'average' was as I feared and hoped against. Part A results were mostly statistically insignificant.
It wasn't "bad", however. There was improvement in P300 scores and two Cogstate metrics at week 5, and in ADSC-ADL at week 12 apparently, which is Part B and where the dosing regimen is more likely therapeutic. I wish they would have shown more Part B interim results.
But this was not "good". It did not match an optimistic interpretation of the abstract. Lots of canny and objective investors sold on the abstract last week. I was only 25% canny, sold a quarter of my holdings on Thursday. What can you do: investing is risk!
Market Data 
Markets 
AI
